#$%^&*AU2012203580A120130117.pdf#####ABSTRACT OF THE DISCLOSURE Compositions and methods are provided lor treating joint conditions, such as osteoarthritis and/or the pain associated therewith. The compositions and methods utilize a first component, namely hyaluronic acid ("IA"), in combination with at least one stabilizer. The composition can include a stabilizer that increases the stability and shelf-life of the HA. In another embodiment, the compositions and methods can also include an additional component, such as one or more glycosaminoglycans ("GAG") or GAG precursors. Examples of GAGs or GAG precursors can include chondroitin sulfate ("CS"), dermatan sulfate, heparin, heparan sulfate, keratan sulfate, and glucosamine ("GlcN). 2021809.1 38
